Acquired Thrombotic Thrombocytopenic Purpura

• FDA approval · 2024-04-11
  FDA Approved: CABLIVI — Supplemental Application (Genzyme Corporation)

  FDA approved a supplemental application for Cablivi (caplacizumab) submitted by Genzyme, resulting in changes to the product labeling.

• FDA approval · 2020-12-16
  FDA Approved: CABLIVI — Supplemental Application (Genzyme Corporation)

  FDA approved a supplemental application for CABLIVI (caplacizumab) filed by Genzyme Corporation.

• FDA approval · 2019-02-06
  FDA Approved: CABLIVI — Original Application (Genzyme Corporation)

  FDA approved CABLIVI (caplacizumab) from Genzyme for the treatment of adults with acquired thrombotic thrombocytopenic purpura.